APR-246 enhances the anticancer effect of doxorubicin against p53-mutant AsPC-1 pancreatic cancer cells
DOI:
https://doi.org/10.21123/bsj.2024.10135Keywords:
APR-246, Combination, Doxorubicin, Pancreatic Cancer, p53 reactivatorAbstract
Pancreatic cancer (PC) is a disease with a high mortality rate, and the early diagnosis of PC is still challenging. The 5-year relative survival rate remains below 8%, and therapeutic strategies are ineffective at increasing patient survival rates. In PC cells, resistance to treatment has been associated with genetic changes that initiate aberrant developmental signaling pathways; therefore, new strategies for treating PC are warranted. Here, we sought to explore the small molecule p53 reactivator, APR-246, either as a mono-drug or combined with doxorubicin (Doxo) in the p53 mutant (p53-mut) AsPC-1 PC cell line. Cytotoxicity of APR-246 and Doxo was studied alone or in combination with the AsPC-1 cell line with MTT assay. CalcuSyn software was used to calculate the combination index (CI), which was based on the Chou and Talalay technique. Apoptosis was assessed after staining with Acridine orange/ethidium bromide (AO/EB). Morphological alterations were examined under a 200x magnification by an inverted microscope. Gene expression was quantified using quantitative reverse transcription PCR assay (RT-qPCR). APR-246 alone exhibited modest anti-proliferative effects, while Doxo combined with APR-246 showed synergistic effects associated with morphological change; no more enhanced apoptosis was observed, as supported by NOXA gene levels. In conclusion, APR-246, whether monotherapy or combined with Doxo, was hindering the proliferation of p53-mut AsPC-1 PC cells, and further in vitro and in vivo research is warranted.
Received 08/11/2023
Revised 24/12/2023
Accepted 26/12/2023
Published Online First 20/01/2024
References
Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019; 10(1): 10. https://doi.org/10.14740/wjon1166
Blandino G, Di Agostino S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37: 1-13.https://doi.org/10.1186/s13046-018-0705-7
Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol. 2020; 13(1): 1-20.https://doi.org/10.1186/s13045-020-00958-3
Du J, Gong H, Xiao H. Somatic TP53 mutations and comparison of different TP53 functional domains in human cancers: Data analysis from the IARC TP53 database and the National Cancer Institute GDC data portal. Med Data Min. 2021; 4(3): 1-10.https://doi.org/10.12032/MDM2021033003
Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022; 29(5): 946-60.https://doi.org/10.1038/s41418-022-00988-z
Peter S, Alven S, Maseko RB, Aderibigbe BA. Doxorubicin-Based Hybrid Compounds as Potential Anticancer Agents: A Review. Molecules (Basel, Switzerland). 2022; 27(14): 4478.https://doi.org/10.3390/molecules27144478
Mohammed I, Alhammer AH, Arif IS. The p53 reactivator PRIMA-1(MET) synergises with 5-fluorouracil to induce apoptosis in pancreatic cancer cells. Invest New Drugs. 2023; 41(4): 587-95.https://doi.org/10.1007/s10637-023-01380-5
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021; 39(14): 1584-94.https://doi.org/10.1200/jco.20.02341
Menichini P, Monti P, Speciale A, Cutrona G, Matis S, Fais F, et al. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still A Mutant P53-Dependent Affair?. Cells. 2021; 10(1): 98.https://doi.org/10.3390/cells10010098
Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023; 10(4): e272-e83.https://doi.org/10.1016/S2352-3026(22)00403-3
Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Investig New Drugs. 2014; 32: 783-94.https://doi.org/10.1007/s10637-014-0090-9.
Ali SM, Al-Karam LQ, Alhammer AJN. In Vitro Cancer Cells Therapy with Nano-gold Depending on its Optical Properties. Neuroquantology 2022; 20(2): 57.https://doi.org/10.14704/nq.2022.20.2.NQ22025
Alfardan RJBSJ. Small Nuclear RNA 64 (snoRNA64): A novel Tumor Biomarker for Pancreatic Cancer. Baghdad Sci J. 2023; 20((5Suppl.)): 1873-81.https://doi.org/10.21123/bsj.2023.7135
Nashaan FA, Al-Rawi MS, Alhammer AH, Rabie AM, Tomma JH. Synthesis, characterization, and cytotoxic activity of some imides from galloyl hydrazide. Eurasian Chem Commun. 2022; 4(10): 966-75.https://doi.org/10.22034/ecc.2022.340135.1453
Al-Juboori SKE, Al-Juboori SIK. Hepatocellular Carcinoma Prediction and early Diagnosis of Hepatitis B and C viral infection using miR-122 and miR-223 in a sample of Iraqi patients. Baghdad Sci J. 2023; 20(4(SI)): 1520.https://doi.org/10.21123/bsj.2023.9065
Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene. 2008; 27 Suppl 1(Suppl 1): S84-92.https://doi.org/10.1038/onc.2009.46
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1): 31-46.https://doi.org/10.1158/2159-8290.cd-21-1059
Voutsadakis IA. Mutations of p53 associated with pancreatic cancer and therapeutic implications. Ann Hepatobiliary Pancreat Surg. 2021; 25(3): 315-27.https://doi.org/10.14701/ahbps.2021.25.3.315
Guo Y, Tang Y, Lu G, Gu J. p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act. Nutrients. 2023; 15(10): 2259-82.https://doi.org/10.3390/nu15102259
Bykov VJ, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018; 18(2): 89-102.https://doi.org/10.1038/nrc.2017.109.
Yoshikawa N, Kajiyama H, Nakamura K, Utsumi F, Niimi K, Mitsui H, et al. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Oncol Rep. 2016; 35(5): 2543-52.https://doi.org/10.3892/or.2016.4653
Liu J, Huang Y, Liu Y, Chen Y. Irisin enhances doxorubicin-induced cell apoptosis in pancreatic cancer by inhibiting the PI3K/AKT/NF-κB pathway. Med Sci Monit. 2019; 25: 6085.https://doi.org/10.12659/MSM.917625
Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and NoxaAntimyeloma Activity of PRIMA-1Met. Mol Cancer Ther. 2013; 12(11): 2331-41.https://doi.org/10.1158/1535-7163.MCT-12-1166.
Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015; 6(6): e1794.https://doi.org/10.1038/cddis.2015.143
Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, et al. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers. 2021; 13(17): 4476-99.https://doi.org/10.3390/cancers13174476
Basu B, Gourley C, Gabra H, Vergote IB, Brenton JD, Abrahmsen L, et al. PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC). Ann Oncol. 2016; 27: vi123.https://doi.org/10.1093/annonc/mdw368.29
Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016; 6: 21.https://doi.org/10.3389/fonc.2016.00021.
Basile KJ, Aplin AE. Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. Am J Cancer Res. 2012; 2(6): 726-35
Lu T, Zou Y, Xu G, Potter JA, Taylor GL, Duan Q, et al. PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK. Oncotarget. 2016; 7(50): 83017.https://doi.org/10.18632/oncotarget.12940
Yang MC, Lin RW, Huang SB, Huang SY, Chen WJ, Wang S, et al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Cell Cycle. 2016; 15(3): 394-402.https://doi.org/10.1080/15384101.2015.1127470
Almohaidi AMS, Hassan FM, Rothan H. Editorial: Current advances in anti-infective strategies. Baghdad Sci. J. 2023;20(5):1570. https://doi.org/10.21123/bsj.2023.9731
Downloads
Issue
Section
License
Copyright (c) 2024 Baghdad Science Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
